Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
MASAC Recommendation #31- MASAC STATEMENT ON PHASE IV POST LICENSING STUDIES
 

MASAC Recommendation #31

MASAC STATEMENT ON PHASE IV POST LICENSING STUDIES

The National Hemophilia Foundation (NHF) recognizes the importance of phase IV post licensing clinical studies as defined by the Food and Drug Administration (FDA). This mechanism facilitates continuing data collection to examine and guarantee product safety and should also expedite the approval process by the FDA of new therapies which are important to the hemophilia community. Therefore, the NHF urges physicians to participate in phase IV studies and to complete patient data forms in a timely manner for submission to the FDA. In addition, we urge industry (in their consultation with FDA) to develop clinical reporting forms which minimize the efforts of HTC staff in fulfilling FDA requirements for licensure. (NHF medical leadership would be pleased to help towards this end). Financial compensation should be provided for any study that requires data collection that exceeds more than a few minutes of staff time per patient. Post licensure studies are not to be considered as a substitute for clinical trials to seek answers to important scientific questions.